Bipolar I

"You’re manic, manic / There is a chemical in your brain / It’s pouring sunshine and rage / You can never know what to expect / You’re manic, manic" ~ Plumb: Manic

I spoke to someone online in November who asked me if I was bipolar I or II. I was reading the mood-tracking chart that my doctor gave me  (courtesy of GSK via Lamictal) and noticed it mentioned bipolar I.

But I am still left with many questions regarding bipolar disorder:

  • How will it affect me personally?
  • When I have an "episode," what is my husband supposed to do?

The bp diagnosis has explained a lot of things, but prompts so many more questions, which need answers…

intueri hits the spot

Oh. My. Goodness.

Abilify phone booth (side view)Intueri originally wrote the post about seeing Abilify on the side of a phone booth. I thought it was pretty funny and pretty stupid.

I still find it stupid, but even more so now.

I was on the bus heading to work today (I don’t normally take it) . When it reached a red light near the subway, I saw a telephone booth – akin to the one that you see on the right – draped in an Abilify ad. The ad is exactly what you see here. (If you can’t see it, go to Abilify.com and click on the “see our print adverisement!”)

I work near two major colleges with students who all have cell phones. Adults in the area are too busy thinking about their own problems while heading into the subway. (They, too, are likely to own cell phones.) Public telephones are rarely used anymore. So who’s going to read an ad on Abilify, let alone on a public telephone booth?

Some marketing person at Bristol-Myers Squibb probably thought it would be awesome to have an ad for Abilify near two major colleges. “All the college kids that walk by will see it!”

The readable text – from the bus, anyway – was “Treating bipolar disorder takes understanding.”

Understanding of what? Who’ll actually stand there and go, “Yeah, I need understanding” and walk right up to it to read more.

    • “where you’ve been
    • where you want to go
    • how you want to get there”

I’m ready to understand my history, my future, and the plans I should make. Uh-huh, Abilify will help me do that.

“Ask your doctor or health care professional if ABILIFY is right for you.” [emphasis mine]

The bus didn’t stay there long enough for me to see if they included the safety information, but here’s the gist of what they provide:

    • “Acute manic and mixed episodes associated with Bipolar I Disorder
    • Maintaining efficacy in patients with Bipolar I Disorder with a recent manic or mixed episode who had been stabilized and then maintained for at least 6 weeks “

Someone can explain the last part to me a little better? I’m a mixed-episode case, do I qualify for Abilify?

I was under the impression that Abilify (aripiprazole) is an atypical antipsychotic. Antipsychotics should be prescribed for those who have psychosis. (I may be wrong here; I’m still trying to figure out the difference between typical and atypicals.) I don’t have psychosis. I don’t need Abilify. But the few bipolar people who will read that ad – they’re likely to be homeless – will be misled into thinking that they need Abilify to help them. They’ll go their doctors, saying, “I’ve heard Abilify helps people with bipolar disorder, could I perhaps try it?” PCPs will immediately churn out prescriptions and uneducated psychiatrists (yes, they are out there despite their degrees) will say, “Sure, Abilify works for bipolar disorder. Let’s see if it works for you.” The smart psych would say, “I’m not sure if it would be right for you. It’s an atypical antipsychotic that targets Bipolar I patients who have symptoms of psychosis. Let’s try something else instead.”

So I went on my soapbox. Again. But it angers me to see:

    • An Abilify ad on a phone booth. Period.
    • A misleading advertisement geared to all people with bipolar disorder (it doesn’t specify until you get to the fine print) that says, “Try this; it may work for you.”
    • An advertisement for medication. At all.

What’s next? A marketing blitz by Eli Lilly? “Zyprexa doesn’t cause diabetes! Check out zyprexafacts.com for more information!”

Big Pharma never fails to surprise me.

Pharmaceutical roundup

AbilifyNearly every mental health blog I know is talking about this post from intueri.org. It’s definitely worth the read. I don’t know much about Abilify, but I don’t think most uneducated bipolars know that it is prescribed specifically for those with psychosis. On the flip side, I don’t think uneducated PCPs know that tidbit either. A person with bipolar without symptoms of psychosis who asks for Abilify may be in for a rude awakening. [UPDATE: Who paid this chick? I only skimmed the post but I don’t see any negative side effects listed.]

I’m not deep into the pharmaceutical industry like all of these heavyweights: CL Psych, PharmaGossip, and Furious Seasons, among many others whom I may have failed to mention. However, there’s a wealth of information to be found. My newest discovery:

“The approach is called ‘ethical pharmaceuticals,’ and it was unveiled on January 2 by Sunil Shaunak, professor of infectious diseases at Imperial College, and Steve Brocchini of the London School of Pharmacy, the Guardian reports. Their team of scientists in India and the UK, financed by the prestigious Wellcome with technical assistance from the UK government, have developed a method of making small but significant changes to the molecular structure of existing drugs, thereby transforming them into new products, circumventing the long-term patents used by the corporate giants of Big Pharma to keep prices – and profits – high. [emphasis mine] This will give the world’s poorest and most vulnerable people access to life-saving medicines – now priced out of reach – for mere pennies.”

I read the above on CLPsych’s blog (originally from Chris Floyd at truthout) and couldn’t believe what I was reading. It somewhat ties into what I’ve been researching about Neurontin (which will probably be posted later in the day):

“Pfizer has developed a successor to gabapentin [Neurontin’s generic name], called pregabalin (being marketed as Lyrica®). Structurally related to gabapentin [emphasis mine], pregabalin is effective for neuropathic pain associated with diabetes and shingles, and for the treatment of epilepsy and seizures.”

Pfizer, in an attempt to distance itself from the trouble surrounding Neurontin, developed another medicine – pregabalin, which is similarly structured to gabapentin. Pfizer can now claim, “Don’t like Neurontin? You can have Lyrica instead!” Pfizer also tried to pass off the (illegal) off-label marketing practices with Neurontin off to their acquired division Parke-Davis. So now we’ve got two options: Pfizer either has learned from Parke-Davis’ issues with Neurontin or is pretty stupid and pushing Lyrica for off-label usage similar to that of Neurontin’s. No evidence to support either option… yet. But CLPsych delves into an interesting practice that Pharma companies use to circumvent a drug patent running out:

“News Flash — PhRMA does NOT believe in the free market: While PhRMA likes when the market works in their favor, they also believe in circumventing that same market when it comes to competition. When drugs are slated to come off-patent, which would allow generic version of the drug to be made, PhRMA members have increasingly turned to buying off the competition. That’s right; they simply pay the generic manufacturer to not make a generic version of the patented drug, so that the consumer can continue to pay a hefty price for the drug which is still under patent. [emphasis sorta mine]

Wow. That bit of information has left me speechless. Screw the consumer that can’t afford psych meds without health insurance; we as Big Pharma need our DAMN money!!! [end rant]

This practice, called “reverse payments,” is not something new and, at the current moment, is relatively legal. Supposedly, the FTC and the Department of Justice are keeping their eyes on reverse payments and patients can only imagine what might occur in the future. PharmaGossip has more, but slips this bit of info before linking to the Star-Ledger:

“And with the patents on 70 blockbuster drugs — with a total of $48 billion in annual sales — set to expire by 2011, the industry expects reverse-payment deals to proliferate further.”

The FTC and Justice Department better hurry up and step in so we can finally have a generic version of Lipitor!

In all honesty, my mind can’t simply fathom the depths to which Pharma will stoop to make money. (Perhaps because I don’t work directly within the medical industry.) It has me wondering if Pharma is worse than gas companies. Is OPEC more trustworthy than Eli Lilly? I’ll leave it up to you to decide.

Lots of studying to do

I don’t know much about the CATIE study (haven’t researched it yet) but feel free to go to the FREE CATIE breakfast symposium near you.

From the site:

Objectives:
At the end of these educational activities, participants should be able to:

  • Differentiate the clinical outcomes among patients prescribed the various treatment modalities in the CATIE study.
  • Choose an efficacious medication that improves symptoms in patients with schizophrenia who have failed on previous treatments.
  • Choose a tolerable medication to improve compliance in patients with schizophrenia who have discontinued previous treatments.
  • Individualize treatment for patients with schizophrenia based on history of symptoms, ability to tolerate adverse effects, and comorbid illnesses.
  • Discuss the effectiveness of antipsychotic medications for schizophrenia in terms of efficacy, tolerability, and cost.

I’ve heard about the CATIE study from sites like Furious Seasons and Clinical Psychology and Psychiatry, but now that I know it deals with schizophrenia, I’m interested in learning more about it.

CashIn other news, I attended a Bipolar and Depression Support Group tonight and received a presentation from UPenn on a genetics study they are doing to study bipolar disorder. They need 4,000 volunteers with bipolar disorder to help and they currently only have 2,000. If a person qualifies for the study, he or she will receive a $100 compensation. The study closes in December 2007. The following is some more information:

  • Individuals 16 and older with Bipolar I Disorder or Schizo-affective Diorder, Bipolar Type, are eligible to join this study.
  • Participation involves the following:
  1. Completion of questions
  2. A 1-2 hour interview (in person or over the phone)
  3. Small blood sample (drawn at UPenn’s expense)
  4. $100 compensation
  • The study does not change your treatment.
  • No travel required.

I can’t stress enough that people will bipolar disorder should participate in the study. Again, people do NOT need to live in the Philadelphia or Pennsylvania area to participate. People with bipolar disorder who live ANYWHERE in the United States can participate in the study. Please, let’s help make this study a success to improve treatment – not only for ourselves but also for future generations.

Raising Mental Health Awareness

“Suicide is most often the impulsive act of a desperate man. … You can get to a point of desperately wanting to stick a gun in your mouth faster than you can read this sentence.” — Philip Dawdy, Furious Seasons blogger and Seattle Weekly staff writer

AbilifyMy husband and I recently heard about Abilify and wondered why we haven’t heard about it being more widely used in regard to Bipolar I. Well, of course, Abilify has some shady appearing data. Read Dawdy’s post for more info.

Dawdy also has written about suicides occurring in Seattle. He wrote a 10-page (by my count) story for the Seattle Weekly about 2 years ago on raising suicide and mental health awareness. He stresses suicides are not widely reported because the media tend to ignore them unless they involve a public figure, i.e. Kurt Cobain, Elliot Smith. What I understand from my journalism classes is that suicides aren’t reported in the media (TV, print, etc.) because editors, who make those decisions, fear copycat attempts. Reporting about suicide treads a fine line between reporting necessary news and giving readers unnecessary ideas.